The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index; none of the 21 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE: Depression and anxiety are common disorders in inflammatory bowel disease (IBD). Our aim is to prospectively determine the effect of psychiatric treatment on scores for depression, anxiety, quality of life (QoL), and sexual dysfunction in an outpatient population diagnosed with IBD and also anxiety and/or depression disorder. PATIENTS AND METHODS: Patients who scored higher than the cutoff point on the Hospital Anxiety Depression Scale were referred for further structured psychiatric evaluation and determination of the need for psychiatric drug treatment. Patients who underwent drug therapy completed Short Form-36 (SF-36) and the Arizona Sexual Experience Scale at baseline and after 6 months of follow-up. RESULTS: Major depressive disorder and generalized anxiety disorder were the most common diagnoses. After 6 months, 47 patients had completely adhered to drug treatment (group A), whereas 20 were nonadherent (group B). In group A, all domains of SF-36, Arizona Sexual Experience Scale, depression/anxiety scores, and Crohn's disease activity index were statistically improved after treatment when compared with the baseline. In group B, the three domains of SF-36, platelet count, and mean corpuscular volume were worse between baseline and at 6 months. CONCLUSION: In IBD patients having any psychiatric disorder, 6 months of antidepressant drug treatment is associated with an improvement in depression, anxiety, QoL, and sexual functioning scores, as well as an improvement in Crohn's disease activity index. On the other hand, insufficient psychiatric treatment seems to be related to a poor QoL.
Overview
CoChat Summary
## TL;DR
This prospective outpatient study found that 6 months of antidepressant psychiatric treatment in IBD patients with psychiatric disorders was associated with improved depression, anxiety, quality of life, sexual function, and Crohn’s disease activity index. Patients who did not adhere to treatment did not show these benefits and had some worsening of QoL-related measures.
## Key findings
- Of 214 invited IBD outpatients, 177 completed screening; 70 had HADS scores above cutoff, and 67/70 (95.71%) were diagnosed with a psychiatric disorder by SCID-I. The most common diagnosis was major depressive disorder (43.3%).
- After 6 months, the adherent treatment group (group A, n=47) showed statistically significant improvement in HAD-A, HAD-D, all SF-36 domains, ASEX, hemoglobin, and CDAI compared with baseline.
- In the nonadherent group (group B, n=20), SF-36 items SF-3 and SF-8 worsened, and platelet count and mean corpuscular volume were worse between baseline and 6 months.
- Side effects were reported by 19/67 treated patients (33.3%); only 5 of those 19 (26.3%) discontinued medication, and discontinuation was due to new-onset sexual dysfunction (3 cases), weight gain (1), and fatigue/drowsiness (1).
## Methods
- Prospective outpatient study at a single IBD clinic (Marmara University Hospital) from June 1, 2013 to June 1, 2014; 214 sequential IBD outpatients were invited, 177 were analyzed after exclusions.
- Screening used HADS, followed by psychiatrist-administered SCID-I for those above cutoff; patients diagnosed with psychiatric disorder were offered antidepressant treatment and followed for 6 months.
- Outcomes were measured at baseline and 6 months using SF-36, Arizona Sexual Experience Scale (ASEX), disease activity indices (CDAI for Crohn’s disease, modified Mayo score for ulcerative colitis), and laboratory tests; analyses included paired-samples t-tests, between-group tests, correlations, and logistic regression.
## Limitations
- The paper explicitly states that subtype-specific comparisons of IBD were not possible because group A and group B were relatively small.
- The follow-up period was relatively short, as stated in the paper.
- The study population was mostly outpatient patients in remission, so the text notes that findings may not generalize well to more flare-prone patients; this is an evident limitation from the sample described.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
0 Valid · 0 Not valid · 12 Not checked · 33 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, of the 19 patients who had any type of drug-related side effect, only five (26.3%) discontinued the antidepressant medication.”
§ The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease > Results > Side effects
plainn = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“If we compared the mean of the change in each variable between groups A and B, the variation of HAD-A, HAD-D, all SF-36 domains, and all ASEX parameters was statistically more improved in group A than in group B.”
§ The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease > Results > Comparison of variation in each parameter between baseline and final visit (between groups A and B)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The mean changes in CDAI were negatively correlated with the mean changes in QoL items (SF-2 and SF-3).”
§ The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease > Results > Correlation of mean change in variables within group A at 6 months
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The frequency of side effects related to antidepressant usage was nearly one-third (n=19, 33.3%) of all patients.”
§ The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease > Results > Side effects
plainn = 19- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Sixty-seven (95.71%) patients who were above the HADS cutoff points were diagnosed as having any psychiatric disorder, as defined by SCID; the most common psychiatric diagnosis was major depressive disorder (43.3%) (Table 2).”
§ The effects of psychiatric treatment on depression, anxiety, quality of life, and sexual dysfunction in patients with inflammatory bowel disease > Results > Sociodemographic features
plainstates an associationn = 70- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
20 more claims
Create a free account to see all 45 claims and to verify the 21 references still open.
- It may state two separate claims as one. 15
- Probably not a substantial claim. 6
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In one of the only prospective studies of antidepressant use in IBD, individuals with Crohn’s disease and depression who were using a selective serotonin receptor inhibitor or selective noradrenaline receptor inhibitor experienced improvement in anxiety and depression symptoms at six months (p < 0.001) as well as improved disease clinical index scores (P = 0.01) (77).”
From The 2023 Impact of Inflammatory Bowel Disease in Canada: Mental Health and Inflammatory Bowel Disease (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Antidepressant treatment was not associated with a significant improvement in CDAI compared to the control group (mean improvement -62.9 (SD 99.5), P = 0.57)”
From Antidepressants in Inflammatory Bowel Disease: A Systematic Review (2017) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD treatment was found to be associated with an improvement in CDAI in patients with IBD. Intervention: 197.41 (130.60) to 101.08 (65.88) (p=0.011); Control: 58.50 (74.94) to 83.50 (62.68) (p=0.710).”
From Antidepressants in Inflammatory Bowel Disease: A Systematic Review (2017) · cites this paper as Yanartas (2016)
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Yanartas et al. (2016) was at low risk of bias”
From Antidepressants in Inflammatory Bowel Disease: A Systematic Review (2017) · cites this paper as [20]
Experimental — accuracy not yet measuredIn the citing paper
“nor was it associated with improvement in MMS (-1.6 (3.4), P = 0.926).”
From Antidepressants in Inflammatory Bowel Disease: A Systematic Review (2017) · cites this paper as [20]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (1983) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1983.tb09716.x · Cited by 47,139
(1992) · PubMed · Cited by 33,716
Depression and quality of life in older persons: A review
Sivertsen, H., Bjørkløf, G. H., Engedal, K., Selbæk, G., & Helvik, A.-S. (2015) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000437299 · Cited by 14,152
DiMatteo, M. R., Lepper, H. S., & Croghan, T. W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.14.2101 · Cited by 4,177 · cited 1×
“DiMatteo et al 32 have demonstrated depression to be a risk factor for noncompliance with medical treatment.”
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026 · cited 2×
“22 The MMS is another scoring system that calculates the disease activity of UC.”
The Arizona Sexual Experience Scale (ASEX): Reliability and Validity
A. McGahuey, A. J. G. (2000) · Journal of Sex & Marital Therapy · doi:10.1080/009262300278623 · Cited by 1,155 · cited 1×
“It is designed to evaluate the major components of sexual dysfunction: drive, arousal, penile erection/vaginal lubrication, ability to reach orgasm, and satisfaction from orgasm.(20,21) The screening result from ASEX allows rapid detection of sexual dysfunction, and higher scores reflect impaired sexual dysfunction.”
BackgroundLewis, J. D., Chuai, S., Nessel, L., Lichtenstein, G. R., Aberra, F. N., & Ellenberg, J. H. (2008) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20520 · Cited by 964 · cited 1×
“Higher scores mean a worsening of underlying UC disease activity.(24)”
BackgroundDirect Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults
Kappelman, M. D., Rifas–Shiman, S. L., Porter, C. Q., Ollendorf, D. A., Sandler, R. S., Galanko, J. A., & Finkelstein, J. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.012 · Cited by 634
Depression and anxiety in inflammatory bowel disease: A review of comorbidity and management
Graff, L. A., Walker, J. R., & Bernstein, C. N. (2009) · Inflammatory Bowel Diseases · doi:10.1002/ibd.20873 · Cited by 586 · cited 8×
“Another possible explanation for the improvement of biologic parameters with 6 months of psychiatric treatment may be the claimed anti-inflammatory effects of antidepressant drugs.(4,5) Our study population includes mostly patients with IBD in remission, so it should have been more difficult to demonstrate any possibl…”
InfluentialRederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI)
Best, W. R., Becktel, J. M., & Singleton, J. W. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90384-6 · Cited by 562 · cited 1×
“Higher scores mean a worsening of underlying CD activity.(22) The MMS is another scoring system that calculates the disease activity of UC.”
Research works printed but not linked: 2
- [14]First MB Spitzer RL Gibbon M Williams JBW User’s Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders SCID-I: Clinician Version New York American Psychiatric Press 1997
- [30]Vidal A Gómez-Gil E Sans M The impact of anxiety and depression on relapse in patients with inflammatory bowel disease Med Clin (Barc) 2009 132 8 298 302 19264194
Cited by
Depression is associated with more aggressive inflammatory bowel disease
Kochar, B., Barnes, E. L., Long, M. D., Cushing, K. C., Galanko, J., Martin, C. F., Raffals, L. E., & Sandler, R. S. (2018) · American Journal of Gastroenterology · doi:10.1038/ajg.2017.423 · Cited by 178
Etiology and Treatment of Pain and Psychosocial Issues in Patients With Inflammatory Bowel Diseases
Regueiro, M., Greer, J. B., & Szigethy, E. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.10.036 · Cited by 142
The Brain-Gut Axis: Psychological Functioning and Inflammatory Bowel Diseases
Peppas, S., Pansieri, C., Piovani, D., Danese, S., Peyrin-Biroulet, L., Tsantes, A. G., Brunetta, E., Tsantes, A. E., & Bonovas, S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10030377 · Cited by 112
Haj-Mirzaian, A., Amiri, S., Amini-Khoei, H., Hosseini, M.-J., Haj-Mirzaian, A., Momeny, M., Rahimi-Balaei, M., & Dehpour, A. R. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.10.023 · Cited by 100
“Psychiatric comorbidities in IBD patients negatively affect the quality of their lives and the severity of disease in sufferings (van den Brink et al., 2016; Yanartas et al., 2016).”
BackgroundAntidepressants in Inflammatory Bowel Disease: A Systematic Review
Macer, B. J. D., Prady, S. L., & Mikocka-Walus, A. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001059 · Cited by 92
Depression and Anxiety Disorders in Patients With Inflammatory Bowel Disease
Hu, S., Chen, Y., Chen, Y., & Wang, C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.714057 · Cited by 87
“Prevalence and Risk factors Associated With Anxiety and Depression Disorders Compared with the general population, patients with IBD had a higher lifetime rate of psychiatric disorders such as anxiety and depression, which were known to have negative impact on the quality of their lives and the severity of disease (8,…”
BackgroundChronic Unpredictable Mild Stress in Rats Induces Colonic Inflammation
Wei, L., Li, Y., Tang, W., Sun, Q., Chen, L., Wang, X., Liu, Q., Yu, S., Yu, S., Liu, C., et al. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01228 · Cited by 80
“Overall, IBD patients showed an increased frequency of depression and anxiety as compared to that in the general population, and anti-depressant medications have been shown to improve Crohn’s disease activity indices in some IBD patients (Yanartas et al., 2016).”
Sleep and Inflammatory Bowel Disease: An Important Bi-Directional Relationship
Qazi, T., & Farraye, F. A. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy334 · Cited by 73
Mules, T. C., Swaminathan, A., Hirschfeld, E., Borichevsky, G. M., Frampton, C., Day, A. S., & Gearry, R. B. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16616 · Cited by 61
Tarricone, I., Regazzi, M. G., Bonucci, G., Rizzello, F., Carini, G., Muratori, R., Poggioli, G., & Campieri, M. (2017) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2017.07.001 · Cited by 53
Kristensen, M. S., Kjærulff, T. M., Ersbøll, A. K., Green, A., Hallas, J., & Thygesen, L. C. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy367 · Cited by 47
Buspirone alleviates anxiety, depression, and colitis; and modulates gut microbiota in mice
Kim, J.-K., Han, S., Joo, M.-K., & Kim, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-85681-w · Cited by 52
Huang, L., Ma, Z., Ze, X., Zhao, X., Zhang, M., Lv, X., Zheng, Y., & Liu, H. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1189008 · Cited by 48
“Chronic stress was the risk factors and etiology for several gastrointestinal diseases such as functional intestinal disorders and inflammatory bowel diseases (IBDs), and chronic stress also increased the risk of ulcerative colitis (UC) recurrence (Levenstein et al., 2000; Ringel and Drossman, 2001).”
BackgroundPhilippou, A., Sehgal, P., Ungaro, R. C., Wang, K., Bagiella, E., Dubinsky, M. C., & Keefer, L. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab200 · Cited by 43
Development of a Sexual Dysfunction Scale for Women With Inflammatory Bowel Disease
de Silva, P. S., O’Toole, A., Marc, L. G., Ulysse, C. A., Testa, M. A., Julsgaard, M., Ngyuen, D., Ananthakrishnan, A. N., Laursen, T., Højgaard, A. D., et al. (2018) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izy202 · Cited by 43
Sexual Dysfunction in Patients With Chronic Gastrointestinal and Liver Diseases: A neglected Issue
Romano, L., Granata, L., Fusco, F., Napolitano, L., Cerbone, R., Priadko, K., Sciorio, C., Mirone, V., & Romano, M. (2021) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2021.02.002 · Cited by 50
Sexual Dysfunction in Inflammatory Bowel Disease: What the Specialist Should Know and Ask
de Arce, E. P., Quera, R., de Barros, J. R., & Sassaki, L. Y. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s308214 · Cited by 46
“treatment guided by a psychiatrist avoiding antidepressants that potentially impair sexual functioning, for example SSRI,(74) in addition to psychological therapy, is essential to improve the quality of life of patients.(54)”
BackgroundMethodSceats, L. A., Dehghan, M. S., Rumer, K. K., Trickey, A., Morris, A. M., & Kin, C. (2020) · Colorectal Disease · doi:10.1111/codi.14905 · Cited by 33
The Effect of Antidepressants on the Course of Inflammatory Bowel Disease
Hall, B. J., Hamlin, P. J., Gracie, D. J., & Ford, A. C. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/2047242 · Cited by 37
“Limited data, to date, have suggested improvements inmood, inflammatory activity, and quality of life with antidepressant therapy [23, 38].”
Bulut, E. A., & Törüner, M. (2018) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2018.18250 · Cited by 34
Graff, L. A., Geist, R., Kuenzig, M. E., Benchimol, E. I., Kaplan, G. G., Windsor, J. W., Bitton, A., Coward, S., Jones, J. L., Lee, K., et al. (2023) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwad012 · Cited by 30
Mules, T. C., Swaminathan, A., Hirschfeld, E., Borichevsky, G. M., Frampton, C. M., Day, A. S., & Gearry, R. B. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac204 · Cited by 35
Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice
Hatamnejad, M. R., Baradaran Ghavami, S., Shirvani, M., Asghari Ahmadabad, M., Shahrokh, S., Farmani, M., Sherkat, G., Asadzadeh Aghdaei, H., & Zali, M. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980189 · Cited by 28
“(2016) (109) Prospective cohort 67 cases Six-month anti-depressant therapy improved depression, anxiety, and sexual function, as well as the disease activity.”
BackgroundHigh Demand for Psychotherapy in Patients with Inflammatory Bowel Disease
Klag, T., Mazurak, N., Fantasia, L., Schwille-Kiuntke, J., Kirschniak, A., Falch, C., Goetz, M., Malek, N. P., Enck, P., & Wehkamp, J. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001216 · Cited by 28
Hammami, M. B., & Mahadevan, U. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000515 · Cited by 27
Stroie, T. G., Preda, C. M., Istrătescu, D., Ciora, C. A., Croitoru, A. E., & Diculescu, M. (2023) · Medicine · doi:10.1097/md.0000000000033713 · Cited by 28
“It has been demonstrated that receiving psychiatric treatment is associated with improvement not only in anxiety and depression, but also in disease activity, quality of life, and sexual functioning.[3,12] Nonetheless, anxiety and depression are frequently overlooked by clinicians and only a small proportion of patien…”
BackgroundManaging Pain and Psychosocial Care in IBD: a Primer for the Practicing Gastroenterologist
Weaver, E. K., & Szigethy, E. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-0757-7 · Cited by 27
Kesen, O., Kani, H. T., Yanartaş, Ö., Aykut, U. E., Gök, B., Gündüz, F., Yilmaz, Y. N., Ozdogan, O. C., & Alahdab, Y. Ö. (2019) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2019.18679 · Cited by 24
Self-citationLi, Q., He, X., Gao, F., Fan, Y., Zhao, B., Ma, Q., Yan, B., Wang, W., Ma, X., & Yang, J. (2022) · Schizophrenia · doi:10.1038/s41537-022-00244-w · Cited by 22
Yanartaş, Ö., Kani, H. T., Kani, A. S., Demirok, Z. N., Akça, E., Ergün, S., Tezcan, N., Atuğ, Ö., İmeryüz, N., & Sayar, K. (2019) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2019.1589177 · Cited by 18
“[23] Yanartas O, Kani HT, Bicakci E, et al.”
BackgroundResultSelf-citationThe Perception of Physician Empathy by Patients with Inflammatory Bowel Disease
Chiapponi, C., Witt, M., Dlugosch, G. E., Gülberg, V., & Siebeck, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167113 · Cited by 19
Management of Sexual Dysfunction in Gastrointestinal Disorders.
Bedell, A., & Friedlander, A. (2022) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2022.06.012 · Cited by 7
Antidepressant treatment in inflammatory bowel disease: a systematic review and meta-analysis
Weston, F., Carter, B., Powell, N., Young, A. H., & Moulton, C. D. (2024) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002768 · Cited by 21
“The NOS showed that both cohort studies were at low risk of bias [19,20].”
Antidepressant fluoxetine alleviates colitis by reshaping intestinal microenvironment
Teng, S., Yang, Y., Zhang, W., Li, X., Li, W., Cui, Z., Li, M., & Wu, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01538-5 · Cited by 17
Blackwell, J., Alexakis, C., Saxena, S. K., Creese, H., Bottle, A., Petersen, I., Hotopf, M. H., & Pollok, R. (2021) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2020-000588 · Cited by 18
The New Proactive Approach and Precision Medicine in Crohn’s Disease
Zittan, E., Gralnek, I. M., & Berns, M. S. (2020) · Biomedicines · doi:10.3390/biomedicines8070193 · Cited by 14
“One study found that 6 months of antidepressant therapy was associated with decreased anxiety and depression, and improved disease activity (decreased CDAI), QoL, and sexual functioning [76].”
BackgroundExploring the management and treatment of IBD from the perspective of psychological comorbidities
Feng, L., Cai, X., Zou, Q., Peng, Y., Xu, L., Wang, L., Liu, Q., & Lou, T. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241290685 · Cited by 15
“7 Notably, depression can manifest even in patients with IBD in clinical remission.”
BackgroundLiang, C., Chen, P., Tang, Y., Zhang, C., Lei, N., Luo, Y., Duan, S., & Zhang, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.880058 · Cited by 15
“These results differ from the previous longitudinal studies showing insignificant differences in CDAI between groups, probably because their participants were outpatients in remission (23, 60).”
ResultIBD-related mental health disorders: where do we go from here?
Gomez, D. A., Ahmad-waqar, M., Brookes, M., & Kumar, A. (2023) · Frontline Gastroenterology · doi:10.1136/flgastro-2023-102403 · Cited by 17
Developmental defects and behavioral changes in a diet-induced inflammation model of zebrafish
Rehman, S., Gora, A. H., Varshney, S., Dias, J. P., Olsvik, P. A., Fernandes, J. M. O., Brugman, S., & Kiron, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018768 · Cited by 13
wom, P. P. O. S. Q. O. L. A., Velayati, A., Sadatmahalleh, S. J., Ziaei, S., & Kazemnejad, A. (2021) · International Journal of Sexual Health · doi:10.1080/19317611.2021.1954576 · Cited by 11
“(Lorenz et al., 2016; Yanartas et al., 2016).”
Vincenzo, F. D., D’Onofrio, A. M., GAUDIO, A. D., Chiera, E., Ferrajoli, G. F., Pesaresi, F., Simonetti, A., Mazza, M., Kotzalidis, G. D., Pettorruso, M., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136514 · Cited by 10
“Yanartas et al.’s prospective cohort study, involving 67 IBD patients treated with various antidepressant classes, evidenced significant improvements in hemoglobin levels and CDAI scores compared with baseline among individuals who adhered rigorously to the prescribed 6-month treatment regimen [27].”
Sudeep, H. V., Venkatakrishna, K., Raj, A., Reethi, B., & Shyamprasad, K. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14306 · Cited by 9
Chen, L., Cao, H., Zhang, X., Du, X., Guan, Y., Li, M., Chang, A. K., He, X., Li, X., & Bi, X. (2024) · Food & Function · doi:10.1039/d3fo05278h · Cited by 10
Neurological Manifestations and Psychiatric Disorders in the Course of Inflammatory Bowel Diseases
Głuch, P., Swiatek, A., Dudek, P., Fabisiak, A., & Talar‐Wojnarowska, R. (2022) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-3965 · Cited by 9
“After 6 months of antidepressant treatment including SSRI, selective noradrenaline reuptake inhibitors (SNRI) or two of them, patients improved in the symptoms of depression and also in the disease activity of CD [110].”
Singh, A., Bhardwaj, A., Tripathi, A., Ranjan, M. K., Singh, D., Sachdeva, A., Marwah, M., Sadana, K. S., Bansal, N., Mahajan, R., et al. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-08242-3 · Cited by 12
“[16, 17] This accentuates the necessity of identifying and treating psychiatric comorbidities in patients with IBD.”
Hsin, D. C. C., Zhiqin, W., Ibrahim, N., & Ali, R. A. R. (2018) · Intestinal Research · doi:10.5217/ir.2018.00074 · Cited by 7
Fuss, A., & Lease, S. (2022) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001748 · Cited by 7
“19 Each set of questions reflects a symptom criterion according to the DSM-5; items (1-5) for criterion B, intrusive symptoms; items (6-7) for criterion C, avoidance symptoms; items (8-14) for criterion D, negative alterations in cognition; items (15-20) for criterion E, alterations in arousal and reactivity.”
BackgroundPetrillo, A. D., Favale, A., Onali, S., Kumar, A., Abbracciavento, G., & Fantini, M. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155522 · Cited by 9
Effect of escitalopram on an acetic acid‐induced ulcerative colitis model
Firouzabadi, N., Alimoradi, N., Najafizadeh, M., & Najafizadeh, P. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13474 · Cited by 8
IBD LIVE Series—Case 7: The Brain-Gut Connection and the Importance of Integrated Care in IBD
Click, B. H., Greer, J. B., Regueiro, M. D., Hartman, D. J., Davis, P. L., Siegel, C. A., Herfarth, H. H., Rosh, J. R., Shah, S. A., Koltun, W. A., et al. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001101 · Cited by 5
Bertolotti, G., Moroni, L., Burro, R., Spanevello, A., Pedretti, R. F. E., & Giorgetti, G. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s111797 · Cited by 4
Outcomes Associated With Anti‐Depressant Use in Patients With Inflammatory Bowel Disease
Kochar, B. D., Chaaban, L., Kobeissi, L., Fuss, A., Challa, P. K., Melia, J., & Ananthakrishnan, A. N. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70229 · Cited by 3
“…40 people with IBD who were treated with anti-depressants with 20 people with IBD who were not treated concluded that 6 months of anti-depressant treatment is associated with an improvement in quality of life as well as Crohn's disease activity index, but fewer than half this cohort had CD [13].”
Nass, B. Y. S., Dibbets, P., & Markus, C. R. (2025) · Healthcare · doi:10.3390/healthcare13070755 · Cited by 3
“Confirming this, preliminary studies have shown that behavioral and antidepressant therapies for affective and mood disorders have a concomitant positive effect on patients’ GI health and reduce their relapse risk [73,74].”
Skott, E., Söderberg, G., Giacobini, M., Nivins, S., Chen, X., Lindqvist, D., Gissler, M., Sjöberg, K., & Lavebratt, C. (2025) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.15167 · Cited by 2
Otrębski, W., & Krupa-Nowosad, M. (2021) · Health Psychology Report · doi:10.5114/hpr.2021.110690 · Cited by 2
“As most of its symptoms arise from digestive system dysfunction, many CD patients have lower self-image and self-acceptance and complain about an inferior quality of life (Yanartas et al., 2016).”
BackgroundPSYCHOLOGICAL CO-MORBIDITIES AND ILLNESS MANAGEMENT AMONG PATIENTS WITH ULCERATIVE COLITIS
Ishaq, G., & Sultan, H. (2020) · Khyber Medical University Journal · doi:10.35845/kmuj.2020.20144 · Cited by 4
Elbay, R. Y., Karatepe, H. T., Ulaşoğlu, C., & Görmez, A. (2021) · Journal of Clinical Psychology in Medical Settings · doi:10.1007/s10880-021-09780-6 · Cited by 2
The Association Between Depression and Activity of Inflammatory Bowel Disease
Joukar, F., Asgharnezhad, M., Faraji, N., Zeinali, T., Hojati, A., Maveddati, S., Sepehrimanesh, M., Isanazar, A., Mansour-Ghanaei, A., Samadi, A., et al. (2023) · Caspian Journal of Neurological Sciences · doi:10.32598/cjns.9.33.390.1 · Cited by 2
Associations with sexual dysfunction among a Canadian cohort with inflammatory bowel disease
Weizman, A. V., Nguyen, D. M., Targownik, L. E., Mosko, J. D., Bollegala, N. P., Saibil, F. G., Huang, V., Selk, A., & Bernstein, M. A. (2024) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwae048 · Cited by 1
(2019) · Psychiatry and Clinical Psychopharmacology · doi:10.1080/24750573.2019.1606883 · Cited by 1
Hopkins, C. W. P., Butt, H. S., & Moulton, C. D. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001137 · Cited by 1
Sintomas depressivos em pacientes com doença de Crohn e sua relação com o fenótipo da doença
Facanali, C. B. G. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.5.2022.tde-19122022-190513
Psychiatric Management of Patients with Gastrointestinal Disease
Madva, E. N., & Kohrman, S. I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-11844-9.00042-4
Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
Kochar, B. D., & Ananthakrishnan, A. N. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70274
“To counterbalance, other studies, including prospectively conducted randomised controlled trials have demonstrated benefits in mental health outcomes and quality of life, which are critically important outcomes, with antidepressant treatment in patients with IBD [3–6].”
Teng, S., Yang, Y., Zhang, W., Li, X., Li, W., Cui, Z., Min, L., & Wu, J. (2024) · Figshare · doi:10.6084/m9.figshare.26692444
Teng, S., Yang, Y., Zhang, W., Li, X., Li, W., Cui, Z., Min, L., & Wu, J. (2024) · Figshare · doi:10.6084/m9.figshare.26692447
Depression and the Immune Responses
Sunzeri, F. (2026) · Springer eBooks · doi:10.1007/978-3-032-14465-2_10
(2017) · Europe PMC (PubMed Central) · Cited by 86
Metadata
- Authors
- Yanartas, Ö., Kani, H. T., Bicakci, E., Kilic, I., Banzragch, M., Acikel, C., Atug, O., Kuscu, K., Imeryuz, N., & Akin, H.
- Affiliations
- Marmara University (TR)
- Venue
- Neuropsychiatric Disease and Treatment
- Publisher
- Informa UK Limited
- Published
- 2016-03
- Volume
- 12
- Pages
- 673
- ISSN
- 1176-6328 (ISSN-L)
- 1178-2021
- PMC
- PMC4818049
- OpenAlex
- W2316004356
- Cited by
- 69
- References
- 32
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 9 · 2023: 5 · 2022: 10 · 2021: 12 · 2020: 4 · 2019: 5 · 2018: 6 · 2017: 8 · 2016: 3
- FWCI
- 5.92
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Neuropsychiatric Disease and Treatment (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Marmara Üniversitesi
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- inflammatory bowel disease, depression, anxiety, quality of life, sexual dysfunction, antidepressant treatment, medication adherence, CDAI, major depressive disorder, generalized anxiety disorder, psychiatric comorbidity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.